EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

RecruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Migraine Disorders

Interventions

DRUG

Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution

migraine prophylaxis

Trial Locations (1)

RECRUITING

IRCCS San Raffaele Roma, Roma

All Listed Sponsors

lead

IRCCS San Raffaele Roma

OTHER